Last reviewed · How we verify
NCT03961516: CFCGM
Glycemic Characterization and Pancreatic Imaging Correlates in Cystic Fibrosis
trial testing Frequently Sampled Oral Glucose Tolerance Test and CGM in Cystic Fibrosis in 34 participants. Completed in 30 August 2021.
30 August 2021
Quick facts
| Lead sponsor | University Hospitals Cleveland Medical Center |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 34 |
| Start date | 1 May 2019 |
| Primary completion | 30 August 2021 |
| Estimated completion | 30 August 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Frequently Sampled Oral Glucose Tolerance Test and CGM
- MRI Pancreas and Liver
Conditions studied
- Cystic Fibrosis — all drugs for Cystic Fibrosis →
- Cystic Fibrosis-related Diabetes — all drugs for Cystic Fibrosis-related Diabetes →
- Cystic Fibrosis Liver Disease — all drugs for Cystic Fibrosis Liver Disease →
- Pancreatic Steatosis — all drugs for Pancreatic Steatosis →
Sponsor
University Hospitals Cleveland Medical Center
Who can join
Adults 6 to 40, any sex, with Cystic Fibrosis or Cystic Fibrosis-related Diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to investigate the utility of a continuous glucose monitor device (CGM) in screening for cystic fibrosis related diabetes. The investigators will also study how fat deposition in the pancreas and liver impacts insulin production and response, as measured by a frequently sampled oral glucose tolerance test.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03961516
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cystic Fibrosis
Currently open trials in the same condition.
- NCT07437105 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants · Phase 1 · recruiting
- NCT07283770 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants · Phase 1 · recruiting
- NCT07274631 — A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine · recruiting
- NCT06810167 — Assessing Tenapanor as a Treatment of CF-related Constipation. · Phase 3 · recruiting
- NCT06962852 — A Long-term Study to Monitor the Health Status of People With Cystic Fibrosis Who Took Part in a Previous Study With BI · Phase 1, PHASE2 · active not recruiting
Other University Hospitals Cleveland Medical Center trials
Trials by the same sponsor.
- NCT06997198 — Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities · Phase 4 · not yet recruiting
- NCT07379814 — Rectus Abdominis Detrusor Myoplasty for Urinary Retention · not yet recruiting
- NCT07499648 — Baby Steps to Care · NA · not yet recruiting
- NCT07497737 — OMT for Adhesive Capsulitis · Phase 4 · not yet recruiting
- NCT06523166 — Direct Comparison of Cardiac CT With TEE to Evaluate Watchman FLX LAA Occluder Device Characteristics · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03961516 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospitals Cleveland Medical Center
- Last refreshed: 20 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03961516.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing